v3.26.1
Stockholders' equity (Tables)
3 Months Ended
Jun. 30, 2026
Stockholders’ equity [Abstract]  
Summary of Company's Outstanding Warrants Exercisable for Shares of Common Stock
The following table summarizes the Company’s outstanding warrants as of June 30, 2026, all of which are exercisable for shares of Common Stock:
 
                
June 30, 2026  
    No. of
warrants
    Exercise
Price ($)
    Expiration
Date
 
Equity classified warrants
              
Pre-funded warrants issued in connection with September 2023 private placement
  338,252    0.0001     No expiration  
Common warrants issued in connection with February 2025 private placement
  4,418,292    3.395    (1
Pre-funded warrants issued in connection with February 2025 private placement
  657,708    0.0001     No expiration  
 
1.
The February 2025 common warrants will expire on the earlier of: (i) the 60th day after the date the FDA approves the NDA for GTx-104 or (ii) September 25, 2028.